Decentralized Cell Therapy Manufacturing Market

Decentralized Cell Therapy Manufacturing Market to 2031: Size, Share & Growth Report

The global decentralized cell therapy manufacturing market is expected to value at ~USD 0.95 billion in 2026 and is projected to reach ~USD 2.46 billion by 2031, growing at a CAGR of approximately 21.0% during 2026–2031. Market growth is being supported by a fundamental shift in cell therapy production models, with the industry gradually moving beyond reliance on a limited number of large, centralized facilities toward distributed, automated, and closed-system manufacturing platforms positioned closer to patients. Deployment of these systems across hospitals, treatment centers, regional manufacturing hubs, and distributed manufacturing networks is expected to improve production flexibility, reduce logistics requirements, shorten turnaround times, and expand patient access to advanced cell therapies.
Strategic activity in the decentralized cell therapy manufacturing market has accelerated as leading players expand automated manufacturing networks, deploy closed-system platforms at partner sites, and pursue regulatory validation of next-generation manufacturing technologies. In June 2026, Cellares (US) expanded its Series D financing to USD 327 million, to expand commercial-scale operations of its global Smart Factory network, including a new facility in Leiden, Netherlands, planned to become GMP-ready in 2027. In April 2026, Ori Biotech (UK) entered into an MoU with Cell Therapies (Australia) and AdAlta (Australia) to deploy IRO platform in Australia and support broader adoption across Asia Pacific. In May 2026, Ori Biotech and ImmuXell Biotech (China) reported the first patient dosed with a TCR-T therapy manufactured on an IRO system installed at ImmuXell's Shanghai facility, demonstrating transition of the platform into clinical manufacturing. In another significant strategic move, Lonza (Switzerland) received FDA Advanced Manufacturing Technology designation for its automated Cocoon platform in December 2025.

Top 10 Key Takeaways

• North America held the largest share of the market in 2025, supported by the US’s mature CAR-T ecosystem, strong clinical pipeline, established treatment-center network, and investments in automated manufacturing infrastructure.
• Asia Pacific is expected to be the fastest-growing region during 2026–2031, driven by expanding cell therapy programs, localized CAR-T manufacturing, improving treatment access, and increasing deployment of automated platforms across China, India, Japan, South Korea, and Australia.
• Products held the largest market share in 2025, owing to substantial demand for manufacturing platforms, consumables, reagents, bioreactors, and other products required to establish decentralized production capabilities.
• Automated closed-system bioprocessing platforms are expected to be the fastest-growing product segment during the forecast period, as manufacturers increasingly prioritize automation, reduced manual intervention, lower contamination risk, and standardized multi-site production.
• Autologous therapies held the largest share in 2025, primarily driven by CAR-T cell therapy, where patient-specific production, chain-of-identity requirements, and the need to shorten vein-to-vein timelines favor decentralized manufacturing.
• TCR-T cell therapy is expected to be the fastest-growing autologous segment during the forecast period, supported by an expanding development pipeline, growing focus on solid tumors, and increasing adoption of automated manufacturing technologies.
• Hospitals & clinical laboratories held the largest end-user share in 2025, reflecting the growing adoption of point-of-care and near-patient manufacturing models that integrate cell collection, processing, testing, and treatment delivery.
• Pharmaceutical & biotechnology companies are expected to be the fastest-growing end-user segment, as therapy developers increasingly adopt distributed manufacturing networks to support multicenter trials, commercial scalability, and broader geographic access.
• Leading players are accelerating commercialization of decentralized manufacturing platforms, with Cellares (US) expanding its Smart Factory network and Ori Biotech (UK) advancing clinical deployment of its IRO automated manufacturing platform.
• Improved patient access and shorter manufacturing turnaround represent major market opportunities, while multi-site process comparability, regulatory compliance, technology transfer, and consistent product quality remain critical challenges to large-scale adoption.

Why DECENTRALIZED Cell Therapy Manufacturing Market Matters Now

Cell therapy has entered a critical phase of clinical and commercial development, with CAR-T therapies delivering significant outcomes in hematologic malignancies and emerging cell therapy approaches being investigated across autoimmune and other diseases. However, manufacturing capacity, turnaround time, and scalability remain major constraints. Conventional centralized models require patient cells to be transported to specialized manufacturing facilities, processed over several weeks, and shipped back to treatment centers. This model involves complex logistics, substantial labor requirements, batch-specific production, and potential manufacturing delays or failures. Long vein-to-vein timelines can also affect treatment outcomes for patients with rapidly progressing diseases, while the high cost of commercial cell therapies continues to restrict broader patient access.

Decentralized manufacturing addresses these constraints by positioning automated, closed-system manufacturing capabilities at or closer to treatment centers and regional manufacturing hubs. Localized production can reduce transportation requirements, shorten vein-to-vein timelines, improve manufacturing responsiveness, and support standardized production across multiple locations. Automation can further reduce manual processing, labor dependency, contamination risk, and facility requirements. Platforms such as Cellares' Cell Shuttle and Ori Biotech's IRO demonstrate the industry's transition toward scalable and standardized distributed manufacturing. As cell therapy pipelines expand and treatment volumes increase, decentralized manufacturing is becoming increasingly important for improving production scalability, supply-chain resilience, manufacturing economics, and patient access.

Market Trends Shaping DECENTRALIZED Cell Therapy Manufacturing

The decentralized cell therapy manufacturing market is being shaped by advances in automation, distributed production models, regulatory evolution, and the need to improve manufacturing scalability and patient access.

Increasing adoption of automated, closed-system manufacturing platforms is a major market trend, as developers seek to reduce manual intervention, contamination risk, operator variability, and facility requirements. Platforms such as Cellares’ Cell Shuttle and Ori Biotech’s IRO are supporting more standardized, scalable, and reproducible cell therapy manufacturing across distributed sites.

Expansion of regional and near-patient manufacturing networks is accelerating, with companies moving beyond reliance on a limited number of centralized facilities. Locating manufacturing capacity closer to hospitals and treatment centers can reduce transportation requirements, shorten turnaround times, and improve responsiveness as clinical and commercial cell therapy volumes increase.

Regulatory frameworks are increasingly adapting to decentralized manufacturing models, supporting greater clarity around multi-site production, centralized oversight, and GMP compliance. The UK’s point-of-care and modular manufacturing framework represents an important development, providing a structured pathway for medicines manufactured across geographically distributed locations.

Automated quality control and digital process standardization are becoming increasingly important, as manufacturers need to demonstrate consistent product quality across multiple sites. Greater use of real-time monitoring, automated analytics, digital batch records, and standardized operating procedures is expected to support reproducibility, comparability, and regulatory compliance.

Decentralized manufacturing platforms are expanding beyond conventional CAR-T applications, with increasing applicability across TCR-T, NK cell, Treg, gene-edited, and other advanced cell therapies. This broadening therapy pipeline is expected to increase demand for flexible manufacturing platforms capable of supporting multiple processes and product types.

Market Drivers Accelerating Growth

A major factor driving market growth is the reduction in vein-to-vein time through near-patient manufacturing. Decentralized production reduces dependence on long-distance transportation of patient cells and finished therapies, helping shorten manufacturing turnaround. This is particularly important for autologous CAR-T patients with rapidly progressing diseases, where treatment delays can directly affect clinical outcomes.

Another factor driving the market is the shift from cleanroom-intensive production to automated closed-system manufacturing. Platforms such as Cellares’ Cell Shuttle, Ori Biotech’s IRO, and Miltenyi Biotec’s CliniMACS Prodigy integrate multiple processing steps within compact, closed systems. This reduces operator dependency, cleanroom requirements, contamination risk, and facility footprint, improving the feasibility of regional and hospital-based manufacturing.

The expansion of CAR-T into autoimmune diseases is also increasing manufacturing demand. Clinical development in lupus, systemic sclerosis, myositis, and other autoimmune conditions is broadening the potential patient population beyond oncology. Decentralized and automated platforms can provide the scalable manufacturing capacity required to support higher treatment volumes across multiple clinical sites.

Market Challenges and Restraints

A major restraint is the high capital requirement for multi-site GMP deployment. Establishing decentralized manufacturing at hospitals or regional centers requires qualified equipment, controlled manufacturing environments, quality-control capabilities, digital systems, trained personnel, and site validation. Replicating these capabilities across multiple locations can require substantial upfront investment.

Another restraint is the regulatory complexity associated with multi-site manufacturing. Manufacturers must demonstrate consistent CMC controls, product comparability, GMP compliance, batch release procedures, and centralized quality oversight across geographically dispersed sites. Differences in regulatory requirements between countries can further complicate expansion of standardized manufacturing networks.

A key challenge is limited interoperability between proprietary manufacturing platforms. Systems such as Cell Shuttle, IRO, and CliniMACS Prodigy use vendor-specific consumables, software, process configurations, and data architectures. This can complicate technology transfer, restrict platform switching, and increase vendor dependency across multi-site manufacturing networks.

Report Scope

The market covers automated and closed-system cell therapy manufacturing platforms, cell isolation and separation systems, bioreactors, gene editing/transfection systems, cryopreservation solutions, QC tools, consumables, and decentralized manufacturing services that enable production outside conventional centralized facilities. It includes point-of-care, near-patient, and regional distributed manufacturing models for autologous and other advanced cell therapies. The scope excludes conventional centralized CDMO services without decentralized capabilities, standalone research-use equipment, and therapies manufactured entirely within traditional centralized facilities. The market connects to the [INTERNAL LINK: cell therapy market], the [INTERNAL LINK: cell and gene therapy manufacturing market], the [INTERNAL LINK: bioprocessing equipment market], the [INTERNAL LINK: CAR-T cell therapy market], and the [INTERNAL LINK: pharmaceutical automation market].

Market Segmentation

The decentralized cell therapy manufacturing market is segmented by product & service, workflow, end user, and region. By product & service, it includes automated closed-system bioprocessing platforms, cell isolation and separation systems, bioreactors, gene editing/transfection systems, cryopreservation and storage solutions, quality control tools, consumables and reagents, and manufacturing-related services. By workflow, the market covers autologous therapies, including CAR-T, TCR-T, NK cell, and dendritic cell therapies, along with other approaches such as allogeneic and gene-modified cell therapies. By end user, it includes hospitals & clinical laboratories, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Regional coverage spans North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

These segments are closely linked across the decentralized manufacturing ecosystem. For example, a pharmaceutical or biotechnology company may use an automated closed-system platform at a regional or near-patient manufacturing site to produce an autologous CAR-T therapy, while quality control, cryopreservation, and manufacturing services support consistent production across multiple locations.

Segment Insights

By Product & Service

Products held the larger share of the decentralized cell therapy manufacturing market in 2025, supported by demand for automated manufacturing platforms, consumables, reagents, bioreactors, quality control tools, and cryopreservation systems required to establish distributed manufacturing capabilities.

Services are expected to be the fastest-growing segment during the forecast period, driven by increasing outsourcing of cell processing, technology transfer, multi-site manufacturing, and quality and regulatory support as therapy developers expand decentralized production networks.

By Workflow

Autologous therapies held the largest share of the market in 2025, primarily due to the established commercial and clinical use of patient-specific CAR-T therapies, where decentralized manufacturing can reduce logistics complexity and vein-to-vein time.

Other workflows, including allogeneic and emerging gene-modified cell therapies, are expected to be the fastest-growing segment during the forecast period, supported by expanding pipelines and increasing demand for scalable, flexible manufacturing infrastructure.

By End User

Hospitals & clinical laboratories held the largest share of the market in 2025, reflecting the importance of treatment centers in cell collection, near-patient processing, quality testing, and administration of autologous cell therapies.

Pharmaceutical & biotechnology companies are expected to be the fastest-growing end-user segment during the forecast period, as therapy developers increasingly adopt distributed manufacturing models to support multicenter trials, commercialization, and geographic expansion.

By Region

North America

North America held the largest share, primarily driven by the US. Growth is supported by a mature CAR-T ecosystem, strong cell therapy pipeline, established treatment-center network, and increasing investment in automated manufacturing. Cellares (US) operates its commercial-scale Smart Factory in Bridgewater, New Jersey, and was selected for the FDA Manufacturing PreCheck program in June 2026. Its expanded USD 327 million Series D financing is also supporting commercial operations and global manufacturing expansion.

Europe

Europe held the second largest share in the market in 2025. The growth is supported by established CAR-T treatment infrastructure, academic manufacturing capabilities, and an evolving regulatory environment for decentralized production. Germany led the Europe market in 2025, supported by its large CAR-T treatment base, advanced hospital infrastructure, and growing investment in decentralized manufacturing. In August 2025, Fresenius (Germany) launched the EU-backed EASYGEN consortium, supported by approximately USD 9.33 million (EUR 8 million) in funding, to develop an automated, modular platform for manufacturing CAR-T therapies directly at hospitals and treatment centers.

Asia Pacific

Asia Pacific is expected to be the fastest-growing region during the forecast period. China led the Asia Pacific market in 2025, supported by its extensive cell therapy clinical pipeline and growing domestic commercialization activity. In May 2026, Ori Biotech (UK) and ImmuXell Biotech (China) reported the first patient dosed with a TCR-T therapy manufactured using the IRO automated platform at ImmuXell’s Shanghai facility.

Latin America

Latin America represented an emerging decentralized cell therapy manufacturing market in 2025, supported by increasing efforts to develop locally manufactured and more accessible cell therapies. Brazil led the Latin America market in 2025, driven by its comparatively stronger biomedical research, hospital, and advanced therapy infrastructure. The Butantan Institute and University of São Paulo (Brazil) are supporting domestic CAR-T manufacturing through the Nutera advanced therapy facilities, strengthening local production capacity and reducing dependence on imported therapies.

Middle East

The Middle East represents a rapidly developing market in 2025, supported by government-led investment in advanced therapy manufacturing and healthcare localization. Saudi Arabia led the Middle East market in 2025, driven by investments in domestic cell and gene therapy infrastructure. In October 2025, King Faisal Specialist Hospital & Research Centre (Saudi Arabia) launched the country’s first gene and cell therapy manufacturing facility, with planned capacity of up to 2,400 therapeutic doses annually by 2030.

Africa

Africa held a relatively small share of the market in 2025, reflecting limited GMP infrastructure, specialized treatment capacity, and commercial cell therapy availability. However, localized manufacturing initiatives are beginning to emerge, particularly in South Africa, where CAR-T manufacturing programs using automated closed-system technologies are demonstrating the feasibility of producing advanced cell therapies closer to patients.

Key segmentation highlights:

• Products held the larger share in 2025, while services are expected to grow fastest as distributed manufacturing expands.
• Consumables & reagents held the largest product share, while automated closed-system platforms are expected to grow fastest.
• Autologous therapies held the largest share, led by CAR-T, while TCR-T is expected to be the fastest-growing autologous segment.
• Hospitals & clinical laboratories held the largest end-user share, while pharmaceutical & biotechnology companies are expected to grow fastest.
• North America held the largest regional share, while Asia Pacific is expected to be the fastest-growing region.

Key Company Insights

The competitive landscape includes automated manufacturing platform providers, decentralized/point-of-care manufacturing specialists, and cell therapy CDMOs. Key companies considered in the market include Miltenyi Biotec, Lonza, Cellares, Ori Biotech, Thermo Fisher Scientific, Orgenesis, ADVA Biotechnology, Avectas, Catalent, Polpharma, NecstGen, Excellos, and Cellipont Bioservices, among others. Competition is focused on automation, closed processing, manufacturing scalability, technology transfer, and reducing dependence on centralized production.

• Miltenyi Biotec (CliniMACS Prodigy automated cell processing)
• Lonza (Cell & gene therapy CDMO services)
• Cellares (Cell Shuttle/Cell Q/Smart Factory network)
• Ori Biotech (IRO automated manufacturing platform)
• Thermo Fisher Scientific (CTS cell therapy manufacturing solutions)
• Orgenesis (POCare decentralized manufacturing platform)
• ADVA Biotechnology (ADVA X3 point-of-care platform)
• Avectas (SOLUPORE cell-engineering platform)
• Catalent (Cell therapy development & manufacturing services)
• Polpharma (Biologics and cell therapy manufacturing capabilities)
• NecstGen (GMP cell therapy manufacturing)
• Excellos (Cell therapy CDMO services)
• Cellipont Bioservices (Cell therapy CDMO/automated manufacturing)

Cellares (US) is one of the most prominent players in automated decentralized cell therapy manufacturing. Its Cell Shuttle became the first cell therapy manufacturing platform to receive FDA Advanced Manufacturing Technology (AMT) designation in April 2025, followed by selection for the FDA Manufacturing PreCheck program in June 2026. In April 2026, Cabaletta Bio (US) dosed the first patients with rese-cel manufactured on Cell Shuttle and entered a 10-year commercial supply agreement with Cellares. The company also expanded its Series D financing to USD 327 million in June 2026 to support commercial-scale operations and its global Smart Factory network.

Ori Biotech (UK) is advancing an embedded-platform model through its IRO automated manufacturing system. IRO received FDA AMT designation in September 2025 and is being deployed through a Preferred Partner Network that includes Charles River Laboratories (US), CTMC (US), ElevateBio (US), and Kincell Bio (US). In May 2026, the platform entered clinical manufacturing in China through ImmuXell Biotech (China), demonstrating its potential for standardized deployment across partner facilities and geographies.

Miltenyi Biotec (Germany) remains an established provider of decentralized cell processing through its CliniMACS Prodigy platform, which integrates cell selection, engineering, expansion, and formulation within a closed and automated workflow suitable for point-of-care and distributed manufacturing. Lonza (Switzerland), meanwhile, is increasingly positioned as a cell and gene therapy CDMO rather than an automated-platform provider, following the completed divestment of its Personalized Medicine business, including the Cocoon platform, in 2026.

Key company strategy conclusions:

• Cellares holds a strong regulatory position, with Cell Shuttle receiving FDA AMT designation and acceptance into the FDA Manufacturing PreCheck program, alongside clinical manufacturing validation.
• Ori Biotech follows an embedded-platform strategy, deploying IRO within partner facilities to enable distributed manufacturing without building a proprietary manufacturing network.
• Miltenyi Biotec’s CliniMACS Prodigy is an established modular platform supporting automated, closed manufacturing across centralized and point-of-care settings.
• Expansion into autoimmune and emerging cell therapies is broadening manufacturing demand, increasing the need for scalable, multi-product automated platforms.

Recent Developments

• In June 2026, Cellares was accepted into the FDA's inaugural Manufacturing PreCheck cohort, the only cell therapy platform among seven companies nationwide, creating a structured pre-operational FDA review process.
• In July 2026, Cellares and Sonoma Biotherapeutics announced a collaboration to automate manufacturing of SBT-77-7101 on the Cell Shuttle—the first Treg cell therapy onboarded to the platform for poly-refractory rheumatoid arthritis.
• In January 2026, Cellares raised USD 257 million in Series D funding (subsequently extended to USD 327 million), with total funding exceeding USD 600 million, and announced new IDMO facilities planned in the Netherlands and Japan.
• In February 2026, Cellares and Stanford Medicine announced a collaboration to expand automated manufacturing to gene-edited hematopoietic stem cell therapies via Cell Shuttle and Cell Q.
• In January 2025, Cytiva announced a partnership with Cellular Origins to combine the Sefia automated platform with Constellation robotic manufacturing for automated CGT production.

Real-World Use Cases

Cabaletta Bio’s rese-cel program provides a strong clinical use case for automated decentralized manufacturing. In January 2026, the FDA cleared an IND amendment allowing rese-cel to be manufactured on Cellares’ Cell Shuttle, following comparability studies between the automated and established manufacturing processes. In April 2026, the first two patients received Cell Shuttle-manufactured rese-cel, with both GMP batches meeting release specifications. Cabaletta and Cellares subsequently entered a 10-year commercial supply agreement, demonstrating the potential of automated manufacturing to support higher-volume CAR-T production for autoimmune indications.

The Bristol Myers Squibb–Cellares collaboration illustrates both the commercial potential and execution challenges of decentralized manufacturing. BMS had selected Cellares to provide automated manufacturing capacity for Breyanzi across the US, Europe, and Japan, representing a significant large-pharma commitment to distributed production. However, BMS terminated the partnership in August 2026 after determining that Cell Shuttle did not meet Breyanzi’s commercial-scale manufacturing requirements. The development highlights that successful decentralized manufacturing depends not only on automation and capacity, but also on product-specific process compatibility, technology transfer, comparability, and reliable commercial-scale execution.

Conclusion and Future Outlook

Through 2031, decentralized cell therapy manufacturing is expected to become an increasingly important production model for autologous and other advanced cell therapies. Market growth will be supported by the need to reduce vein-to-vein timelines, lower dependence on labor-intensive cleanroom operations, expand manufacturing capacity, and improve treatment accessibility. The adoption of automated closed-system platforms, regulatory initiatives such as FDA AMT designation and Manufacturing PreCheck, and the expansion of CAR-T therapies into oncology and autoimmune indications are expected to further support market development. Increased use of digital process monitoring, automated quality control, and advanced analytics is also expected to improve consistency across distributed manufacturing sites.

The competitive landscape is expected to favor companies that can combine automation, regulatory compliance, multi-site standardization, and scalable manufacturing economics. However, successful commercialization will depend on effective technology transfer, process comparability, product-specific platform compatibility, and consistent quality across locations. For pharmaceutical companies, CDMOs, hospitals, and investors, long-term opportunities will depend on the ability to establish reliable and commercially viable manufacturing networks closer to treatment centers while maintaining regulatory and product-quality requirements.

Frequently Asked Questions (FAQ)

1. How big is the decentralized cell therapy manufacturing market?

The decentralized cell therapy manufacturing market is valued at ~USD 0.95 billion in 2026 and is projected to reach about ~USD 2.46 billion by 2031. North America held the largest market share in 2025, supported by the established US CAR-T ecosystem, advanced treatment infrastructure, and investments in automated and distributed manufacturing.

2. What is the decentralized cell therapy manufacturing market growth rate?

The market is forecast to grow at a CAGR of approximately ~21.0% from 2026 to 2031. Asia Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding cell therapy pipelines, localized manufacturing, and increasing adoption of automated platforms across China, India, Japan, South Korea, and Australia.

3. Which segment leads the decentralized cell therapy manufacturing market?

By product & service, products held the highest market share in 2025, supported by demand for manufacturing platforms, consumables, reagents, and processing equipment. Within products, consumables & reagents held the largest share, while automated closed-system bioprocessing platforms are expected to be the fastest-growing product segment during the forecast period.

4. Who are the key players in the decentralized cell therapy manufacturing market?

Key players include Miltenyi Biotec, Lonza, Cellares, Ori Biotech, Thermo Fisher Scientific, Orgenesis, ADVA Biotechnology, Avectas, Catalent, Polpharma, NecstGen, Excellos, and Cellipont Bioservices, among others.

5. What are the factors driving the decentralized cell therapy manufacturing market?

Major growth drivers include the need to reduce vein-to-vein timelines, the shift from cleanroom-intensive production to automated closed-system manufacturing, and the expansion of CAR-T therapies into autoimmune diseases. These factors are increasing demand for scalable manufacturing capacity closer to treatment centers.

Speak With Our Analyst

The decentralized cell therapy manufacturing market is evolving rapidly as automation, distributed production models, regulatory requirements, and manufacturing economics become increasingly important to commercial strategy. Detailed analysis of platform capabilities, decentralized manufacturing models, therapy-specific requirements, and regional adoption can support informed decisions on manufacturing strategy, technology selection, partnerships, and investment. MarketsandMarkets can help you go deeper: request a sample of the full study, speak with our analyst about your specific questions, or customize the scope to your target platform types, therapy areas, and geographies. Reach out to explore how this intelligence can inform your cell therapy manufacturing strategy, platform selection, or investment thesis.